HORMONAL BIOMARKERS AND MOLECULAR SUBGROUPS IN EC 143 6 Outcome ER or PR expression Figure 2A-E shows the 5-year DSS curve of the three-tiered ER risk classification within the entire cohort and the molecular subgroups. In the entire cohort, patients with ER 90-100% expression showed a significantly better DSS when compared to ER 20-80% (P<0.001) and ER 0-10% (P<0.001). Patients with ER 20-80% had a significant higher 5-year DSS compared to ER 0-10% (P<0.001) (Figure 2A). Across all molecular subgroups, patients with ER 90100% expression showed the most favorable 5-year DSS (Figure 2B-E). Within POLEmut EC, patients with ER 90-100%, 20-80% and 0-10% revealed no significantly different 5-year DSS (respectively, 100.0%, 100.0% and 92.0%) For MMRd tumors, patients with ER 90100% and 20-80% or 0-10% revealed significantly different 5-year DSS (respectively, 96.0% vs 80.0% P=0.017 and 96.0% vs 71.0% P=0.002) (Figure 2C). Within patients with p53mut no significant differences in 5-year DSS were found between the three ER subgroups (Figure 2D). Within NSMP tumors, patients with ER 0-10% had a significant worst 5-year DSS of 48.0% compared to ER 90-100% (96.0%, P<0.001) and compared to ER 20-80% ( 88.0%, P<0.001)). (Figure 2E). Figure 3A-E shows the 5-year DSS curve of the three-tiered PR risk classification within the entire cohort and the molecular subgroups. In the entire cohort, patients with PR 90-100% expression showed a significantly better DSS when compared to PR 20-80% (P=0.003) and PR 0-10% (P<0.001). Patients with ER 20-80% had a significant higher 5-year DSS compared to ER 0-10% (P<0.001) (Figure 3A). Across all molecular subgroups, patients with PR 90-100% expression showed the most favorable 5-year DSS and PR 0-10% the worst (Figure 3B-E). Within POLEmut and MMRd tumors, no significant different 5-year DSS was revealed within the three subgroups of PR expression (Figure 3B-C). Patients with p53mut EC and PR 90-100% had a 5-year DSS of 100%, this was significantly different compared to PR 20-80% (62.0%, P=0.032) and PR 0-10% (48.0% P=0.006) (Figure 3D). Within NSMP tumors, patients with PR 90-100% had an excellent 5-year DSS of 98.0%, for PR 20-80% the 5-year DSS was 88.0% and PR 0-10% showed the worst 5-year DSS of 56.0%. All were significantly different from each other (Figure 3E). Across all molecular subgroups, PR 0-10%, p53mut, lympho-vascular space invasion (LVSI) and FIGO stage III-IV remained independent prognostic for reduced DSS. Whereas PR 90100% and POLEmut remained independent prognostic for improved DSS (Table 2).
RkJQdWJsaXNoZXIy MTk4NDMw